Abstract:High expression of MYCN, PRMT5 and E2F1 in neuroblastoma cells derived from high‐risk disease causes a deregulated alternative RNA splicing programme and resistance to cell death. The pharmacological inhibition of PRMT5, or E2F1 inactivation, restores normal splicing, rendering neuroblastoma cells sensitive to apoptosis. Our findings therefore identify PRMT5 as a potential therapeutic target for the treatment of high‐risk neuroblastoma. Protein arginine methyltransferase 5 (PRMT5) is over‐expressed in a wide variety of cancers and is implicated as having a key oncogenic role, achieved in part through its control of the master transcription regulator E2F1. We investigated the relevance of PRMT5 and E2F1 in neuroblastoma (NB) and found that elevated expression of PRMT5 and E2F1 occurs in poor prognosis high‐risk disease and correlates with an amplified Myelocytomatosis viral‐related oncogene, neuroblastoma‐derived (MYCN) gene. Our results show that MYCN drives the expression of splicing factor genes that, together with PRMT5 and E2F1, lead to a deregulated alternative RNA splicing programme that impedes apoptosis. Pharmacological inhibition of PRMT5 or inactivation of E2F1 restores normal splicing and renders NB cells sensitive to apoptosis. Our findings suggest that a sustained cancer‐relevant alternative RNA splicing programme desensitises NB cells to apoptosis, and identify PRMT5 as a potential therapeutic target for high‐risk disease.

Sustained cancer‐relevant alternative RNA splicing events driven by PRMT5 in high‐risk neuroblastoma